Archive | August, 2009

EDAP Receives U.S. FDA 510(k) Approval for Sonolith I-Sys – Shares Jump On News

by Editor on August 23, 2009 in Editorial, Medical Devices, linkedin

France based EDAP has announced 510k approval for it’s new lithotripsy device. Marc Oczachowski, EDAP’s Chief Executive Officer, said, “We are very pleased that the U.S. FDA has granted 510(k) approval for Sonolith I-Sys, which marks a clear milestone for EDAP, further validates our technology and supports our objective to expand the Sonolith I-Sys into [...]

Read full story • Comments { 0 }

France Medical Market Update – Winners And Losers

by Editor on August 20, 2009 in China Manufacturing, Editorial, Home Healthcare, Medical Devices

The medical durables business in France continues to suffer with recently acquired Corona (operation of Paramount in Japan) announcing a plant closure, with production moving to China. This in contrast to medical device manufacturers Urgo in the Burgundy region and Vygon that have announced good results and resultant investment programs.

Read full story • Comments { 0 }

Invacare Sues Drive Medical For Patent Infringement

by Editor on August 13, 2009 in Editorial, Home Healthcare, linkedin

Invacare is seeking injunctive relief and suing Drive Medical for alleged patent infringement related to it’s bed products as well as it’s rollator. Invacare had previously announced in one of it’s presentations that it would be focussing more on protecting it’s intellectual property and this action may well partially stem from this. As more and [...]

Read full story • Comments { 0 }

Invacare Stock +31% YTD – US Homecare Market Turnaround

by Frank Barlin on August 2, 2009 in Editorial, linkedin

With Invacare shares trading at the psychological level above $20 for the first time (in a long time), far out performing the S&P 500, you have to ask whether the base US homecare market is in turnaround mode (despite competitive bidding, Chinese direct market entrants etc) – or is it just Invacare’s perseverant ability in [...]

Read full story • Comments { 0 }